Andrew R. Colin, M.D., Joins AIT’s Scientific Advisory Board
REHOVOT, Israel, August 7, 2013 /PRNewswire/ –
Israeli biomed company AIT [http://www.ait-pharm.com ] (Advanced Inhalation Therapies
Ltd.), a leader in the development of nitric oxide therapeutics for the treatment of
infectious respiratory diseases, announced today the appointment of Andrew R. Colin, M.D.,
to its scientific advisory board.
Dr. Colin is a professor of pediatrics and director of the Division of Pediatric
Pulmonology at the University of Miami Health System. He also serves as co-director of the
Pediatric Cystic Fibrosis program. He is on the medical staff of Jackson Memorial Hospital
in Miami, Florida. He is certified by the American Board of Pediatrics in pediatric
“I am delighted to welcome Dr. Andrew R. Colin to AIT’s SAB. His tremendous expertise
in the field of respiratory disease and pulmonology brings invaluable knowledge to AIT.
This is a pivotal time for AIT as activities related to our Phase II clinical trials are
expected in the coming months,” says Professor Yossef Av-Gay, a director at AIT and a
professor at the University of British Columbia in Vancouver, Canada.
“It is my privilege to be part of AIT, an innovative company with a leading team of
researchers with proven results in clinical trials,” said Dr. Colin. “I look forward to
supporting AIT in the development of new therapeutics for patients with insufficient
treatment options that lead to serious consequences.”
AIT focuses on the development of unique nitric oxide formulations for the treatment
of respiratory infectious diseases, including bronchiolitis, cystic fibrosis, pneumonia
and asthma. The company is currently conducting Phase II trials for bronchiolitis in
infants. Mid-study results demonstrated the safety of AIT’s nitric oxide formulation in
AIT (http://www.ait-pharm.com) is an Israeli biomed company focused on the
development and commercialization of formulations from nitric oxide for the treatment of
infectious diseases. The company was founded in 2011 by Mor Research Applications, a
subsidiary of Clalit Health Services, Israel’s largest health management organization.
The company is conducting Phase II trials on bronchiolitis after successful completion
of Phase I trials. AIT develops products for the treatment of bronchiolitis, pneumonia,
cystic fibrosis and asthma.
Contact information Racheli Vizman, COO, AIT 2 Derech Meir Weisgal Rehovot 9632605, Israel E-mail: email@example.com Direct: +972-8-684-3313 Mobile: +972-52-565-9922
SOURCE AIT – Advanced Inhalation Therapies Ltd.